Table 2.
General lab findings before (baseline) and after (endpoint) receiving therapy.
| Clinical parameter | Normal range | Baseline TCZ-HCQ | Baseline TCZ-RMV | P-Value | Endpoint TCZ-HCQ | Endpoint TCZ-RMV | P-value |
|---|---|---|---|---|---|---|---|
| C-reactive protein level, mg/dl | 0−8 | 97 (67.8−139.2) | 125 (43.7−210.8) | 0.12 | 26 (13.7−79.3) | 20.1 (6.4−40.7) | 0.07 |
| Ferritin level, ng/mL | Male | 540.5 (377.5−1082) | 673 (381−1408) | 0.49 | 337 (280.3−626.8) | 1044 (506−1563.5) | <0.001 |
| 12−300 | |||||||
| Female | |||||||
| 12−150 | |||||||
| D-Dimer level, μg/mL | 0−0.5 | 0.48 (0.34−0.88) | 0.58 (0.28−1.2) | 0.41 | 0.23 (0.13−0.68) | 0.52 (0.32−2.5) | <0.001 |
| PaO2/FiO2 (P/F) ratio | >400 | 120.5 (99.6−218.8) | 113.5 (91.3−176.8) | 0.08 | 295.5 (182.3−386) | 280 (115−325.3) | 0.25 |
| Lactate dehydrogenase level (LDH), IU/L | 120−250 | 516 (351.8−710) | 397 (270−518) | 0.002 | 312 (251.8−465.5) | 370 (279−637) | 0.049 |
| TLC(×109/L) | 1.1−3.2 | 10.1 (5.2−13.2) | 7.6 (5.5−10.4) | 0.15 | 7.7 (6.1−10.7) | 10.7 (8.2−15.3) | <0.001 |
| Absolute lymphocyte count% | 18−45% | 9 (6−15) | 13 (9−17) | 0.07 | 11.5(9−20) | 8 (6−9) | 0.002 |
| ALT(IU/L) | 7−40 | 38 (24−57) | 37 (24−52) | 0.85 | 75.5 (48.5−201.8) | 68 (45.8−201.8) | 082 |
| AST(IU/L) | 13−35 | 42 (26−63) | 39.8 (27−60) | 0.93 | 55.5 (32.3−88.3) | 53 (31.3−87.3) | 0.77 |
Data are expressed as median (IQR).